Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies
Authors:
Open Access
- 14 September 2017
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (18) , 5329-5338
Abstract
Survival of children with cancers has dramatically improved over the past several decades. This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease, and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified “driver” genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents. Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the paradigm of precision medicine in the hopes of improving outcomes while minimizing toxicities. In this review, we will discuss the biologic rationale for molecularly targeted therapies in genomically defined subsets of pediatric leukemias, solid tumors, and brain tumors. Clin Cancer Res; 23(18); 5329–38. ©2017 AACR.Keywords
This publication has 90 references indexed in Scilit:
- Targeting MYCN in Neuroblastoma by BET Bromodomain InhibitionCancer Discovery, 2013
- Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectBritish Journal of Cancer, 2012
- Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling PathwaysClinical Cancer Research, 2012
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group StudyClinical Cancer Research, 2011
- Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemiaBlood, 2011
- RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastomaProceedings of the National Academy of Sciences, 2011
- Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase HypersensitivityClinical Pharmacology & Therapeutics, 2010
- Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cellsProceedings of the National Academy of Sciences, 2009
- A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcomaNature Medicine, 2009